Aristada is a brand name for aripiprazole lauroxil, an extended-release injectable antipsychotic medication used to treat schizophrenia and schizoaffective disorder in adults [1]. It is administered intramuscularly and is designed to release the active drug slowly over time, reducing the need for frequent dosing [2].
How does Aristada work for schizophrenia?
Aristada contains aripiprazole, which is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and an antagonist at serotonin 5-HT2A receptors [1]. This mechanism helps to rebalance dopamine and serotonin activity in the brain, which are thought to be involved in the symptoms of schizophrenia [3]. The lauroxil ester formulation is a prodrug that is hydrolyzed in the body to release aripiprazole, providing sustained plasma concentrations [1].
What is the difference between Aristada and Abilify?
Aristada (aripiprazole lauroxil) and Abilify (aripiprazole) both contain the active ingredient aripiprazole. The key difference lies in their formulation and delivery. Abilify is an oral tablet, while Aristada is an extended-release intramuscular injection [1][4]. This means Aristada provides long-acting delivery of aripiprazole, reducing the frequency of administration compared to daily oral Abilify [2][4].
When does the patent for Aristada expire?
Patent exclusivity for Aristada is a complex matter involving multiple patents related to the drug's composition, formulation, and method of use. Generally, brand-name drug patents provide market exclusivity for a certain period, after which generic versions can be developed and approved. Information on specific patent expiry dates for Aristada can be found through resources that track pharmaceutical patents, such as DrugPatentWatch.com [5].
Can generic versions of Aristada be developed?
The development of generic versions of Aristada, known as biosimilars in the case of injectable biologics, depends on patent expirations and regulatory approvals. Once the relevant patents expire and regulatory hurdles are cleared, manufacturers can seek approval to market generic alternatives [5]. The process for approving generic injectables may have specific considerations compared to oral generics.
What are the potential risks and side effects of Aristada?
Common side effects associated with Aristada can include injection site reactions, insomnia, headache, constipation, nausea, and increased appetite [1]. More serious potential side effects may include tardive dyskinesia, neuroleptic malignant syndrome, metabolic changes (such as hyperglycemia and dyslipidemia), and orthostatic hypotension [3]. Patients should discuss all potential risks with their healthcare provider.
How is Aristada administered?
Aristada is administered by a healthcare professional as an intramuscular injection [1]. It is available in different strengths and dosing intervals, typically administered monthly or every two months, depending on the specific formulation and treatment plan [2].
Where can I find more information about Aristada's patent status?
Detailed information regarding the patent landscape for Aristada, including patent numbers, expiry dates, and any ongoing litigation, can be found on specialized pharmaceutical patent databases. DrugPatentWatch.com provides such comprehensive data for various medications [5].
*
**Sources:
[1] https://www.aristada.com/
[2] https://www.drugpatentwatch.com/drugs/aristada/
[3] https://www.rxlist.com/aristada-drug.htm
[4] https://www.abilify.com/
[5] https://www.drugpatentwatch.com/